Cargando...

Bone Is a Target for the Antidiabetic Compound Rosiglitazone

Rosiglitazone is an FDA-approved oral antidiabetic agent for the treatment of type 2 diabetes. This compound improves insulin sensitivity through the activation of the nuclear receptor, peroxisome proliferator-activated receptor-γ (PPAR-γ). In addition to sensitizing cells to insulin, the PPAR-γ2 is...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: RZONCA, S. O., SUVA, L. J., GADDY, D., MONTAGUE, D. C., LECKA-CZERNIK, B.
Formato: Artigo
Idioma:Inglês
Publicado: 2003
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1855213/
https://ncbi.nlm.nih.gov/pubmed/14500573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/en.2003-0746
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!